-
公开(公告)号：KR1020090095791A
公开(公告)日：2009-09-10
申请号：KR1020080020935
申请日：2008-03-06
Applicant: 성균관대학교산학협력단
IPC: C07C69/52
CPC classification number: C07C67/31 , C07B2200/09 , C07C67/343 , C07C69/73 , C07C69/732 , C07C69/738 , C07C255/57 , C07C311/19 , C07F7/1852
Abstract: A beta-substituted Morita-Baylis-Hillman derivative, its preparation method, and its stereoisomer are provided to obtain a compound useful as an anticancer drug or an antiviral agent and useful for the treatment of the infectious disease caused by the bacteria which are parasitic within cells such as tuberculosis and leprosy. A beta-substituted Morita-Baylis-Hillman derivative is represented by the formula 1, wherein R_1a and R_1b are independently hydrogen, halo, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy or aryl group; X_1 is OR_4, or NR_(5a)R_(5b); X_2 is oxygen, sulfur or NR_6; R_2 is hydrogen, halo, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy or aryl; R_3a and R_3b are independently hydrogen, halo, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy or aryl; and methyl-2-(1-hydroxy-2-oxopropyl)hexadeca-2-noate is excluded in the compound of the formula 1.
Abstract translation: 提供β-取代的Morita-Baylis-Hillman衍生物及其制备方法及其立体异构体以获得可用作抗癌药物或抗病毒剂的化合物，并且可用于治疗由寄生在其中的细菌引起的感染性疾病 细胞如结核病和麻风病。 β-取代的Morita-Baylis-Hillman衍生物由式1表示，其中R_1a和R_1b独立地为氢，卤素，羟基，烷基，环烷基，烯基，炔基，烷氧基或芳基; X_1为OR_4，或NR_（5a）R_（5b）; X_2是氧，硫或NR_6; R 2是氢，卤素，羟基，烷基，环烷基，烯基，炔基，烷氧基或芳基; R_3a和R_3b独立地是氢，卤素，羟基，烷基，环烷基，烯基，炔基，烷氧基或芳基; 并且在式1的化合物中不包括甲基-2-（1-羟基-2-氧代丙基）十六烷-2-基。
-
公开(公告)号：KR1020090063771A
公开(公告)日：2009-06-18
申请号：KR1020070131256
申请日：2007-12-14
Applicant: 성균관대학교산학협력단
Abstract: A beta-substituted morita-baylis-hillman derivative is provided to be used as an anti-cancer agent or antiviral agent, and to treat infectious disease caused by bacteria which is parasitic on cells. A beta-substituted morita-baylis-hillman derivative has a structure represented by chemical formula 1. In chemical formula 1, R1a and R1b independently show hydrogen, hollow, hydroxy, alkyl, cycloalkyl, alkenyl, alkenyl, alkoxy or aryl, wherein one or more carbon atoms of alkyl, cycloalkyl, alkenyl, alkynyl or alkoxy can form a double bond with an oxygen atom; and X1 shows OR4 or NR5aR5b; X2 shows oxygen, sulfur or NR6.
Abstract translation: 提供β-取代的苦参 - 山lis素衍生物作为抗癌剂或抗病毒剂，并用于治疗寄生在细胞上的细菌引起的感染性疾病。 化学式1中，R 1a和R 1b独立地表示氢，中空，羟基，烷基，环烷基，烯基，烯基，烷氧基或芳基，其中一个或多个 烷基，环烷基，烯基，炔基或烷氧基的更多碳原子可与氧原子形成双键; X1表示OR4或NR5aR5b; X2表示氧，硫或NR6。
-
公开(公告)号：KR102090949B1
公开(公告)日：2020-03-19
申请号：KR1020180142797
申请日：2018-11-19
Applicant: 성균관대학교산학협력단
IPC: C07C29/143 , C07C33/20 , B01J31/14
-
公开(公告)号：KR1020140075823A
公开(公告)日：2014-06-20
申请号：KR1020120133221
申请日：2012-11-22
Applicant: 성균관대학교산학협력단
CPC classification number: C07B41/12 , B01J31/146
Abstract: The present invention relates to a chiral oxazaborolidinium ion catalyst and to an oxazaborolidinium ion which is used as a catalyst in a Roskamp reaction of making diazoester and aldehydes react to produce a chiral-beta-keto ester in the presence of a Lewis acid catalyst. The objective of the present invention is to provide a chiral-beta-keto ester compound which has high stereoselectivity at an alpha location.
Abstract translation: 本发明涉及手性恶唑硼鎓离子催化剂和恶唑硼鎓鎓离子，其在Roskamp反应中用作催化剂，其制备重氮酯和醛在路易斯酸催化剂存在下反应生成手性β-酮酯。 本发明的目的是提供在α位置具有高立体选择性的手性β-酮酯化合物。
-
公开(公告)号：KR1020080100886A
公开(公告)日：2008-11-21
申请号：KR1020070046877
申请日：2007-05-15
Applicant: 주식회사 푸드사이언스 , 성균관대학교산학협력단 , 연세대학교 산학협력단 , 한국기초과학지원연구원
IPC: C07D471/04 , A61P31/12 , A61P35/00
Abstract: An octahydro indeno derivative is provided to have a high biological activity, to have a high cytotoxin to cancer cells with a minimum amount and to be used as an anti-cancer drug or an antibiotic. A composition of treating and preventing cancers includes a compound indicated by a chemical formula 1 and a pharmaceutically allowed carrier. In the chemical formula 1: X is oxygen, sulfur or NH; R1 is hydrogen, hollow, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl or alkoxy; R2 and R3 are independently hydrogen, hollow, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryl or heteroaryl; R4a and R4b are hydrogen, hollow, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl or alkoxy; R5a and R5b are hydrogen, hollow, hydroxy, alkyl, alkenyl, alkynyl or alkoxy; R6a and R6b are hydrogen, hollow, hydroxy, alkyl, alkenyl, alkynyl, alkoxy or the carbonyl radical; R7a and R7b are the hydrogen, hollow, hydroxy, alkyl, alkenyl, alkynyl or alkoxy; R8 is hydrogen, hollow, hydroxy, alkyl, alkenyl, alkynyl or alkoxy; and R9a and R9b are hydrogen, hollow, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryl or heteroaryl.
Abstract translation: 提供八氢茚并衍生物以具有高生物活性，以最小量对癌细胞具有高细胞毒素，并用作抗癌药物或抗生素。 治疗和预防癌症的组合物包括由化学式1表示的化合物和药学上允许的载体。 在化学式1中：X是氧，硫或NH; R1是氢，中空，羟基，烷基，环烷基，烯基，炔基或烷氧基; R2和R3独立地是氢，中空，羟基，烷基，环烷基，烯基，炔基，烷氧基，芳基或杂芳基; R4a和R4b是氢，中空，羟基，烷基，环烷基，烯基，炔基或烷氧基; R5a和R5b是氢，中空，羟基，烷基，烯基，炔基或烷氧基; R6a和R6b是氢，中空，羟基，烷基，烯基，炔基，烷氧基或羰基; R7a和R7b是氢，中空，羟基，烷基，烯基，炔基或烷氧基; R8是氢，中空，羟基，烷基，烯基，炔基或烷氧基; R9a和R9b是氢，中空，羟基，烷基，环烷基，烯基，炔基，烷氧基，芳基或杂芳基。
-
Patent Agency Ranking
-
公开(公告)号：KR101777923B1
公开(公告)日：2017-09-12
申请号：KR1020150165713
申请日：2015-11-25
Applicant: 성균관대학교산학협력단
IPC: C07C45/72 , C07C45/75 , C07C49/213
Abstract: 본발명의α-삼차아릴케톤의합성방법은키랄붕소루이스산(chiral boron Lewis acid) 촉매하에서, 아릴다아이조알칸(Aryldiazoalkanes)과알데하이드(Aldehyde)를반응시켜α-삼차아릴케톤(α-tertiary aryl ketones)을합성한다.
-
公开(公告)号：KR101494094B1
公开(公告)日：2015-02-16
申请号：KR1020130108853
申请日：2013-09-11
Applicant: 성균관대학교산학협력단
IPC: C07C45/86 , C07C49/603 , B01J31/12
Abstract: β-기능화 사이클릭 이논의 입체 선택적 합성방법이 개시된다. 옥사자보로리디늄 이온 촉매의 존재하에서 비기능화 사이클릭 이논과 다이아조아세테이트를 반응시켜 β-기능화 사이클릭 이논을 입체 선택적으로 합성한다. 이러한 합성방법에 따르면 단일 스텝으로 β-기능화 사이클릭 이논을 고효율 및 입체 선택적으로 합성할 수 있다.
Abstract translation: 本发明提供了一种立体选择性合成β-官能化环烯酮的方法。 通过在氧氮杂硼鎓离子催化剂的存在下使非官能化环烯酮与重氮基乙酸酯反应，立体选择性地合成了β-官能化环烯酮。 根据该方法，可以通过单一步骤以高效率立体选择性地合成β-官能化环状酮。
-
公开(公告)号：KR1020100131757A
公开(公告)日：2010-12-16
申请号：KR1020090050500
申请日：2009-06-08
Applicant: 성균관대학교산학협력단
Inventor： 류도현
IPC: C07C67/44 , C07C69/732 , B01J31/02
Abstract: PURPOSE: A method for enantioselectively synthesizing novel beta-substituted morita-baylis-hillman ester is provided to efficiently prepare products by enantioselective property for beta-substituted morita-baylis-hillman ester with optical activity. CONSTITUTION: A method for preparing a compound of below chemical formula 1 comprises the steps of: reacting a compound of chemical formula 2 with a compound of chemical formula 3 under the presence of a catalyst of chemical formula 4 and a solvent to prepare a compound of chemical formula 5; and substituting iodine of a compound of chemical formula 5 to prepare the compound of below chemical formula 1.
Abstract translation: 目的：提供一种对映选择性合成新型β-取代的苦参 - 山茱萸酯的方法，通过具有光学活性的β-取代的苦参 - 山梨糖醇酯的对映选择性有效制备产物。 构成：制备化学式1化合物的方法包括以下步骤：使化学式2的化合物与化学式3的化合物在化学式4的催化剂和溶剂的存在下反应，以制备化合物 化学式5; 并用化学式5的化合物代替碘以制备化学式1以下的化合物。
-
公开(公告)号：KR101881215B1
公开(公告)日：2018-08-16
申请号：KR1020160117923
申请日：2016-09-13
Applicant: 성균관대학교산학협력단
IPC: C07D207/09 , B01J31/02
Abstract: 본발명의화합물, 이를이용하는비대칭마이클첨가반응을이용한화합물의제조방법, 및페니버트화합물의제조방법에서, 본발명의화합물은하기화학식 1로나타낸다; [화학식 1]상기화학식 1에서, L은또는를나타내고(이때, X는황 또는산소를나타낸다), R은수소, 탄소수 1 내지 5을갖는알킬기, 탄소수 6 내지 12을갖는아릴기또는벤질기를나타내며, R는탄소수 6 내지 12를갖는아릴기를나타내고, R은수소또는탄소수 1 내지 12를갖는아릴기를나타내되, R, R및 R의수소들은각각독립적으로탄소수 1 내지 5를갖는알킬기로치환될수 있다.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.021 seconds)
